

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH OSTEOARTHRITIS

1. Paladin: **Pennsaid [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2010.
2. Pfizer: **Flector (diclofenac epolamine) patch**. In: *US Monograph*. New York, NY: Pfizer; 2018.
3. Zeng C, Wei J, Persson MSM, Sarmanova A, Doherty M, Xie D, Wang Y, Li X, Li J, Long H *et al*: **Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies**. *Br J Sports Med* 2018, **52**(10):642-650.
4. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D *et al*: **2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee**. *Arthritis Care Res (Hoboken)* 2020, **72**(2):149-162.
5. Surgeons AAoO: **Management of osteoarthritis of the knee (non-arthroplasty) evidence-based clinical practice guideline**. In.: American Academy of Orthopaedic Surgeons; 2021.
6. Surgeons AAoO: **Management of osteoarthritis of the knee hip evidence-based clinical practice guideline**. In.: American Academy of Orthopaedic Surgeons; 2017.
7. Department of Veterans Affairs/Department of Defense: **VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis**. In.; 2020.
8. Ebell MH: **Osteoarthritis: Rapid Evidence Review**. *Am Fam Physician* 2018, **97**(8):523-526.
9. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M *et al*: **OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis**. *Osteoarthritis Cartilage* 2019, **27**(11):1578-1589.
10. **The Top 300 of 2019** [<https://clincalc.com/DrugStats/Top300Drugs.aspx>]
11. Manara M, Bortoluzzi A, Favero M, Prevete I, Scire CA, Bagnato G, Bianchi G, Ceruso M, Checchia GA, D'Avola GM *et al*: **Italian Society for Rheumatology recommendations for the management of hand osteoarthritis**. *Reumatismo* 2013, **65**(4):167-185.
12. Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, Doherty M, Geenen R, Hammond A, Kjekouk I *et al*: **EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis**. *Ann Rheum Dis* 2013, **72**(7):1125-1135.

13. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M *et al*: **OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.** *Osteoarthritis Cartilage* 2008, **16**(2):137-162.
14. Kloppenburg M, Kroon FP: **2018 update of the EULAR recommendations for the management of hand osteoarthritis.** 2018.
15. NICE: **Osteoarthritis.** In: *NICE Guideline.* vol. NG177. London: National Institute for Health and Care Excellence; 2014.
16. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P: **American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.** *Arthritis Care Res (Hoboken)* 2012, **64**(4):465-474.
17. Brown GA: **AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition.** *J Am Acad Orthop Surg* 2013, **21**(9):577-579.
18. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H *et al*: **OARSI guidelines for the non-surgical management of knee osteoarthritis.** *Osteoarthritis Cartilage* 2014, **22**(3):363-388.
19. Piuze NS, Manner P, Levine B: **American Academy of Orthopaedic Surgeons Appropriate Use Criteria: Management of Osteoarthritis of the Hip.** *J Am Acad Orthop Surg* 2018, **26**(20):e437-e441.
20. Jevsevar DS, Shores PB, Mullen K, Schulte DM, Brown GA, Cummins DS: **Mixed Treatment Comparisons for Nonsurgical Treatment of Knee Osteoarthritis: A Network Meta-analysis.** *JAAOS - Journal of the American Academy of Orthopaedic Surgeons* 2018, **26**(9):325-336.
21. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: **Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology.** *Arthritis Rheum* 1995, **38**(11):1541-1546.
22. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: **Viscosupplementation for the treatment of osteoarthritis of the knee.** *Cochrane Database Syst Rev* 2006(2):CD005321.
23. Rutjes AW, Juni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S: **Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.** *Ann Intern Med* 2012, **157**(3):180-191.
24. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE: **Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.** *Ann Intern Med* 2015, **162**(1):46-54.

25. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: **Intraarticular corticosteroid for treatment of osteoarthritis of the knee.** *Cochrane Database Syst Rev* 2006(2):CD005328.
26. Pekarek B, Osher L, Buck S, Bowen M: **Intra-articular corticosteroid injections: a critical literature review with up-to-date findings.** *Foot (Edinb)* 2011, **21**(2):66-70.
27. Dubois RW, Melmed GY, Henning JM, Laine L: **Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy.** *Aliment Pharmacol Ther* 2004, **19**(2):197-208.
28. Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA: **Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.** *Arthritis Rheum* 2010, **62**(6):1592-1601.
29. Leipzig RM: **That was the year that was: an evidence-based clinical geriatrics update.** *J Am Geriatr Soc* 1998, **46**(8):1040-1049.
30. Bhalra N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA *et al*: **Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.** *Lancet* 2013, **382**(9894):769-779.
31. Griffin MR: **High-dose non-steroidal anti-inflammatories: painful choices.** *Lancet* 2013, **382**(9894):746-748.
32. McGettigan P, Henry D: **Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies.** *PLoS Med* 2011, **8**(9):e1001098.
33. Excellence NifHaC: **Non-steroidal anti-inflammatory drugs.** In., vol. KTT13. London; 2016.
34. Burmester G, Lanasa A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A *et al*: **The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.** *Ann Rheum Dis* 2011, **70**(5):818-822.
35. Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM: **Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data.** *BMJ* 2017, **357**.
36. Lanza FL, Chan FK, Quigley EM: **Guidelines for prevention of NSAID-related ulcer complications.** *Am J Gastroenterol* 2009, **104**(3):728-738.

37. Lanza FL: **A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.** *Am J Gastroenterol* 1998, **93**(11):2037-2046.
38. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J: **Prevention of NSAID-induced gastroduodenal ulcers.** *Cochrane Database Syst Rev* 2002(4):CD002296.
39. Scheiman JM: **The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.** *Arthritis Res Ther* 2013, **15** Suppl 3:S5.
40. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M *et al*: **OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.** *Osteoarthritis Cartilage* 2010, **18**(4):476-499.
41. DynaMed: **Degenerative joint disease of the hip.** In. Ipswich (MA): EBSCO Information Services; 2014.
42. Felson DT: **Clinical practice. Osteoarthritis of the knee.** *N Engl J Med* 2006, **354**(8):841-848.
43. DynaMed: **Degenerative joint disease of the knee.** In. Ipswich (MA): EBSCO Information Services; 2014.
44. DynaMed: **Degenerative joint disease of the ankle.** In. Ipswich (MA): EBSCO Information Services; 2014.
45. DynaMed: **Degenerative joint disease of the lower back.** In. Ipswich (MA): EBSCO Information Services; 2014.
46. Kjekken I, Smedslund G, Moe RH, Slatkowsky-Christensen B, Uhlig T, Hagen KB: **Systematic review of design and effects of splints and exercise programs in hand osteoarthritis.** *Arthritis Care Res (Hoboken)* 2011, **63**(6):834-848.
47. Egan MY, Brousseau L: **Splinting for osteoarthritis of the carpometacarpal joint: a review of the evidence.** *Am J Occup Ther* 2007, **61**(1):70-78.
48. Villafane JH, Cleland JA, Fernandez-de-Las-Penas C: **The effectiveness of a manual therapy and exercise protocol in patients with thumb carpometacarpal osteoarthritis: a randomized controlled trial.** *J Orthop Sports Phys Ther* 2013, **43**(4):204-213.
49. Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA: **Topical NSAIDs for chronic musculoskeletal pain in adults.** *Cochrane Database Syst Rev* 2016, **4**:CD007400.

50. Rothacker DQ, Lee I, Littlejohn TW, 3rd: **Effectiveness of a single topical application of 10|x% trolamine salicylate cream in the symptomatic treatment of osteoarthritis.** *J Clin Rheumatol* 1998, **4**(1):6-12.
51. Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dincer F, Dziedzic K, Hauselmann HJ, Herrero-Beaumont G *et al*: **EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).** *Ann Rheum Dis* 2007, **66**(3):377-388.
52. Brosseau L, Yonge KA, Robinson V, Marchand S, Judd M, Wells G, Tugwell P: **Thermotherapy for treatment of osteoarthritis.** *Cochrane Database Syst Rev* 2003(4):CD004522.
53. Yildirim N, Filiz Ulusoy M, Bodur H: **The effect of heat application on pain, stiffness, physical function and quality of life in patients with knee osteoarthritis.** *J Clin Nurs* 2010, **19**(7-8):1113-1120.
54. Kean WF, Kean CA, Hogan MG: **Osteoarthritis.** In: *Therapeutics.* Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
55. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP: **Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.** *Aliment Pharmacol Ther* 2010, **32**(10):1240-1248.
56. Kean WF, Kean CA, Hogan MG: **Osteoarthritis.** In: *Therapeutics.* Edited by Jovaisas B, April 2018 edn. Ottawa (ON): Canadian Pharmacists Association; 2018.
57. Association CP: **Acetaminophen [CPhA monograph].** In: *CPS.* Ottawa (ON): Canadian Pharmacists Association; 2012.
58. Johnson&Johnson: **Tylenol Arthritis (Acetaminophen ER).** In: *US Product Monograph.* January 2018 edn. Washington, PA USA: Johnson&Johnson; 2018.
59. CPhA: **Acetaminophen [CPhA monograph].** In: *CPS.* Nov 2016 edn. Ottawa (ON): Canadian Pharmacists Association; 2016.
60. BC Renal Agency: **Renal Analgesic Brochure.** In.: BC Renal Agency; 2011.
61. Benson GD, Koff RS, Tolman KG: **The therapeutic use of acetaminophen in patients with liver disease.** *Am J Ther* 2005, **12**(2):133-141.
62. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong K, Sangkuhl CF, Thorn CF, Altman RB, Klein TE: **Pharmacogenomics Knowledge for Personalized Medicine.** *Clinical Pharmacology & Therapeutics* 2012, **92**(4):414-417.
63. Pfizer: **Celebrex** In: *Canada Product Monograph.* May 31, 2017 edn: Pfizer; 2017.

64. Pfizer: **Celebrex** In: *US Product Monograph*. New York, NY USA: ; 2018.
65. Association CP: **Nonsteroidal Anti-inflammatory Drugs (NSAIDs) [CPhA Monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
66. **Osteoarthritis in Peripheral Joints- Diagnosis and Treatment**. In. Edited by BC Guidelines and Protocols Committee; 2009.
67. ULC SP: **Celecoxib [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
68. GenMed: **Celecoxib Monograph, GD Canada**. In: *Canada Product Monograph*. July 18, 2017 edn. Kirkland, Quebec: GenMed; 2017.
69. Pharmaceuticals N: **Voltaren [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
70. Mylan: **Diclofenac Potassium** In: *US Product Monograph*. August 2017 edn. Morgantown, WV USA: Mylan Pharmaceuticals Inc.; 2017.
71. Carlsbad: **Diclofenac Sodium Delayed Release**. In: *US Product Monograph*. May 2016 edn. Carlsbad, CA: Carlsbad Technology, Inc.; 2016.
72. Novartis: **Voltaren (diclofenac)**. In: *CA Product Monograph*. July 18, 2018 edn. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc. ; 2018.
73. INC. AP: **Diflunisal**. In: *Product Monograph*. Vaughan, Ontario: AA PHARMA INC.; 2014.
74. Cadila: **Diflusinal**. In: *US Product Monograph*. June 2017 edn. Baddi, India: Cadila Healthcare Ltd. ; 2017.
75. Lee M, Jensen B, Regier L: **NSAIDS & COXIB ANALGESICS: Drug Comparison Chart**. In: *RxFiles drug comparison charts*. Edited by Edition t. Saskatoon, SK: Saskatoon Health Region; 2017.
76. AA_Pharma_Inc: **Diflunisal**. In: *Product Monograph*. Vaughan, Ontario: AA PHARMA INC.; 2014.
77. Verbeeck R, Tjandramaga TB, Mullie A, Verbesselt R, Verberckmoes R, De Schepper PJ: **Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency**. *Br J Clin Pharmacol* 1979, **7**(3):273-282.
78. Mylan: **Flurbiprofen** In: *US Product Monograph*. May 2016 edn. Morgantown, WV USA: Mylan Pharmaceuticals Inc.; 2016.

79. Limited TC: **Teva-Flurbiprofen**. In: *Product Monograph*. Toronto, Ontario: Teva Canada Limited; 2015.
80. Aphen: **Ibuprofen**. In: *US Product Monograph*. October, 2017 edn. Cookeville, TN USA: Aphen: Aphen Pharma Solutions; 2017.
81. ApoTEX INC.: **Apo-Ibuprofen**. In: *Product Monograph*. Toronto, Ontario: Apotex Inc.; 2017.
82. Heritage: **Ketoprofen** In: *US Product Monograph*. May 2018 edn. East Brunswick, NJ USA: Heritage Pharma Inc; 2018.
83. AA Pharma INC.: **Ketoprofen**. In: *Product Monograph*. Vaughan, Ontario: AA Pharma Inc; 2011.
84. Inc. AP: **Ketoprofen [product monograph]**. In. Ontario: AA Pharma Inc.; 2011.
85. Genentech: **Naproxen Sodium**. In: *US Product Monograph*. October 2010 edn. South San Francisco, CA: Genentech USA, Inc.; 2010.
86. APOTEX INC.: **Apo-Naproxen**. In: *Product Monograph*. Toronto, Ontario: Apotex Inc; 2015.
87. CPhA: **Nonsteroidal Anti-inflammatory Drugs (NSAIDs) [CPhA Monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
88. Pfizer: **Arthrotec**. In: *Canada Product Monograph*. May 26, 2017 edn. Kirkland, Quebec: Pfizer Canada; 2017.
89. Pfizer: **Arthrotec** In: *US Product Monograph*. New York, New York: Pfizer US; 2010.
90. Health_Canada: **Diclofenac - Lowered Maximum Dose**. In: *Health Canada Advisory*. October 6, 2014 edn: Pfizer Canada; 2014.
91. Pfizer: **Arthrotec [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.
92. AstraZeneca: **Vimovo (naproxen/esomeprazole)**. In: *Canada Product Monograph*. April 27, 2018 edn. Mississauga, Ontario: AstraZeneca Canada Inc.; 2018.
93. AstraZeneca: **Vimovo**. In: *US Product Monograph*. June 2018 edn. Lake Forest, IL USA: AstraZeneca; 2018.
94. AstraZeneca: **Vimovo [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.
95. ANI: **Etodolac**. In: *US Product Monograph*. August 2015 edn. Baudette, MN: ANI Pharmaceuticals; 2015.

96. INC. AP: **Etodolac**. In: *Product Monograph*. Vaughan, Ontario: AA PHARMA INC.; 2010.
97. Maccagno A, Di Giorgio E, Romanowicz A: **Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout**. *Curr Med Res Opin* 1991, **12**(7):423-429.
98. AA_Pharma_Inc: **Etodolac** In: *Canada Product Monograph*. January 30, 2018 edn. Vaughan, Ontario: AA Pharma; 2018.
99. Iroko: **Tivorbex (Indomethacin)**. In: *US Product Monograph*. May 2016 edn. Philadelphia, PA USA: Iroko Pharmaceuticals; 2016.
100. Teva Canada Limited: **Teva-Indomethacin**. In: *Product Monograph*. Toronto, Ontario: Teva Canada Limited; 2015.
101. Arfè A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H *et al*: **Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study**. *BMJ* 2016, **354**.
102. Ltd BI: **Mobicox**. In: *Product Monograph*. Burlington, Ontario: Boehringer Ingelheim Ltd; 2014.
103. Badlissi F: **Gout**. In: *BMJ Best Practice*. 2018.
104. Boehringer: **Mobic (meloxicam)**. In: *US Product Monograph*. May 2016 edn. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2016.
105. Apotex: **Meloxicam** In: *Canada Product Monograph*. April 20, 2015 edn. Toronto, Ontario: Apotex Inc; 2015.
106. INC. A: **Apo-Piroxicam**. In: *Product Monograph*. Weston, Ontario: Apotex Inc.; 2010.
107. Pfizer: **Feldene (piroxicam)**. In: *US Product Monograph*. April 2017 edn. New York, NY: Pfizer; 2017.
108. Actavis: **Sulindac**. In: *US Product Monograph*. May 2016 edn. Parsippany, NJ: Actavis Pharma; 2016.
109. Limited TC: **Teva-Sulindac**. In: *Product Monograph*. Toronto, Ontario: Teva Canada Limited; 2011.
110. INC. AP: **Tenoxicam**. In: *Product Monograph*. Toronto, Ontario; 2010.
111. **Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain: Part B Recommendations for Practice**. In., vol. Version 5.6: National Opioid Use Guideline Group (NOUGG); 2010.

112. West-Ward: **Codeine Sulfate** In: *US Product Monograph*. December 2016 edn. Eatontown, NJ USA: West-Ward Pharmaceuticals Corp.; 2016.
113. Riva: **Codeine**. In: *CA Product Monograph*. Blainville, Canada: LABORATOIRE RIVA INC.; 2018.
114. Williams DG, Patel A, Howard RF: **Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability**. *British Journal of Anaesthesia* 2002, **89**(6):839-845.
115. Tseng C-Y, Wang S-L, Lai M-D, Lai M-L, Huang J-d: **Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes***. *Clinical Pharmacology & Therapeutics* 1996, **60**(2):177-182.
116. Zhou S-F: **Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance**. *Clinical Pharmacokinetics* 2009, **48**(11):689-723.
117. Vevelstad M, Pettersen S, Tallaksen C, Brors O: **O-demethylation of codeine to morphine inhibited by low-dose levomepromazine**. *Eur J Clin Pharmacol* 2009, **65**(8):795-801.
118. Lotsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmoller J, Geisslinger G: **Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?** *Pain* 2009, **144**(1-2):119-124.
119. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: **The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype**. *Clinical Pharmacology & Therapeutics* 2008, **83**(2):234-242.
120. Janssen: **Tylenol with Codeine**. In: *US Product Monograph*. December 2018 edn. Titusville, NJ USA: Janssen Pharmaceuticals Inc; 2018.
121. Janssen: **Tylenol with Codeine**. In: *Canada Product Monograph*. November 20, 2018 edn. Markham, Ontario: Janssen Inc; 2018.
122. Janssen: **Ultram**. In: *Canada Product Monograph*. April 5, 2018 edn. Toronto, Ontario: Janssen Inc; 2018.
123. Janssen: **Ultram**. In: *US Product Monograph*. September 2018 edn. Titusville, New Jersey USA: Janssen Inc; 2018.
124. Vertical: **Conzip (tramadol ER)**. In: *US Monograph*. September, 2018 edn. Bridgewater, NJ: Vertical Pharmaceuticals; 2018.
125. ULC SP: **Tramadol/Acetaminophen [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.

126. Janssen: **Ultracet Monograph**. In: *US Product Monograph*. July 2017 edn. Titusville, New Jersey: Janssen Pharmaceuticals, Inc.; 2017.
127. Janssen: **Tramacet**. In: *Canada Product Monograph*. April 5, 2018 edn. Toronto, ON: Janssen Inc; 2018.
128. CPhA: **Opioids**. In: *CPhA Monograph*. September, 2018 edn. Ottawa, ON: Canadian Pharmacists Association; 2018.
129. Actavis: **Kadian**. In: *US Product Monograph*. April 2014 edn. Parsippany, NJ: Actavis Pharma Inc; 2014.
130. Purdue: **MS-IR (morphine immediate release)**. In: *CA Product Monograph*. Pickering, ON: Purdue Pharma; 2018.
131. Bristol-Myers Squibb: **Percocet/Percocet-Demi [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2014.
132. Endo: **Percocet** In: *US Product Monograph*. July 2018 edn. Malvern, PA: Endo Pharmaceuticals Inc.; 2018.
133. Teva: **Oxycocet (oxycodone/acetaminophen)**. In: *CA Product Monograph*. Toronto, Ontario: Teva Canada Limited; 2018.
134. Purdue: **Oxycontin**. In: *US Product Monograph*. September 2018 edn. Stamford, CT USA: Purdue Pharma; 2018.
135. Purdue: **Oxy-IR (oxycodone immediate release)**. In: *CA Product Monograph*. Pickering, Ontario: Purdue Pharma; 2018.
136. Purdue: **Dilaudid (hydromorphone)**. In: *CA Product Monograph*. Pickering, ON: Purdue Pharma; 2018.
137. Purdue: **Dilaudid**. In: *US Product Monograph*. December 2016 edn. Stamford, CT USA: Purdue Pharma; 2016.
138. Mallinckrodt: **Exalgo (hydromorphone 24hr ER tablets)**. In: *US Monograph*. 03/2013 edn. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals; 2013.
139. Cardone DA, Tallia AF: **Joint and soft tissue injection**. *Am Fam Physician* 2002, **66**(2):283-288.
140. Douglas RJ: **Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency**. *Int J Clin Pract* 2012, **66**(7):699-704.
141. Merck: **Celestone Soluspan [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.

142. Merck Canada Inc.: **Celestone Soluspan**. In: *Prescribing Information*. Kirkland, Quebec: Merck Canada Inc.; 2017.
143. Merck: **Celestone Soluspan**. In: *US Product Monograph*. April 2018 edn. Whitehouse Station, NJ USA: MERCK & CO., INC.; 2018.
144. Merck: **Celestone Soluspan (betamethasone acetate/betamethasone sodium phosphate IA injection)**. In: *CA Product Monograph*. Kirkland, QC: Merck Canada Inc.; 2017.
145. Pfizer: **Depo-Medrol [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.
146. Pfizer: **Depo-Medrol**. In: *US Product Monograph*. July 2018 edn. New York, NY USA: Pfizer 2018.
147. Pfizer: **Depo-Medrol (methylprednisolone acetate IA injection)**. In: *CA Product Monograph*. Kirkland, Quebec Pfizer Canada Inc.; 2017.
148. Squibb B-M: **Kenalog-40**. In: *US Product Monograph*. June 2018 edn. Princeton, NJ USA: Bristol-Myers Squibb Company; 2018.
149. Bristol-Myers_Squibb: **Kenalog 40 (triamcinolone acetonide IA injection)**. In: *CA Product Monograph*. Montréal, Canada: Bristol-Myers Squibb Canada; 2017.
150. Pendopharm: **Monovisc [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association.
151. Tribute: **NeoVisc [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association.
152. Pendopharm: **OrthoVisc [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association.
153. Association CP: **Capsaicin Derivatives [CPhA monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2012.
154. Health NC: **Voltaren Emulgel [product monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2015.
155. GlaxoSmithKline: **Voltaren Gel**. In: *US Product Monograph*. February 2018 edn. Warren, NJ USA: GlaxoSmithKline Consumer Healthcare; 2018.
156. Horizon: **Pennsaid** In: *US Product Monograph*. May 2016 edn. Lake Forest, IL: Horizon Pharma USA Inc; 2016.

157. Inc. SH: **Famotidine Tablets**. In: *Product Monograph*. Dieppe, New Brunswick: Sanis Health Inc.; 2014.
158. Valeant: **Pepcid**. In: *US Product Monograph*. June 2016 edn. Bridgewater, NJ USA: Valeant Pharmaceuticals North America; 2016.
159. CPhA: **Histamine H2-receptor Antagonists (H2RAs)**. In: *Product Monograph*. CPhA; 2013.
160. Government B: **Modernized RDP - H2RAs**. In: *Poster*. 2016.
161. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI: **Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs**. *N Engl J Med* 1996, **334**(22):1435-1439.
162. Taha AS, McCloskey C, Prasad R, Bezlyak V: **Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial**. *Lancet* 2009, **374**(9684):119-125.
163. Targownik LE: **Dyspepsia and Peptic Ulcer Disease**. In: *Therapeutics [Internet]*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2014.
164. Schuster B: **Acid Suppression Drugs: Evidence, Tips & Pearls**. In: *RxFiles drug comparison charts*. Online edn. Saskatoon, SK: Saskatoon Health Region; 2017: 67.
165. Sanis: **Famotidine** In: *CA Product Monograph*. Dieppe, New Brunswick: Sanis Health Inc.; 2014.
166. Manlucu J, Tonelli M, Ray JG, Papaioannou A, Youssef G, Thiessen-Philbrook HR, Holbrook A, Garg AX: **Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence**. *Nephrol Dial Transplant* 2005, **20**(11):2376-2384.
167. PENDOPHARM: **Axid (nizatidine)**. In: *CA Product Monograph*. Montréal, CANADA: PENDOPHARM; 2014.
168. Mylan: **Nizatidine** In: *US Product Monograph*. October 2016 edn. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2016.
169. Simon B, Muller P: **Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients**. *Scand J Gastroenterol Suppl* 1994, **206**:25-28.
170. Inc. G: **Zantac**. In: *Product Monograph*. Mississauga, Ontario: GlaxoSmithKline Inc.; 2015.
171. GlaxoSmithKline: **Zantac**. In: *US Product Monograph*. June 2018 edn. Research Triangle Park, NC: GlaxoSmithKline; 2018.

172. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA *et al*: **ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents**. *J Am Coll Cardiol* 2008, **52**(18):1502-1517.
173. Apotex: **Apo-ranitidine**. In: *CA Product Monograph*. Toronto, Ontario: Apotex Inc; 2016.
174. Association CP: **Histamine H2-receptor Antagonists [CPhA monograph]**. In: *CPS*. Ottawa (ON): Canadian Pharmacists Association; 2012.
175. Canada A: **Nexium**. In: *Product Monograph*. Mississauga, ON: AstraZeneca; 2016.
176. AstraZeneca: **Nexium**. In: *US Product Monograph*. June 2018 edn. Wilmington, DE: AstraZeneca; 2018.
177. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, Naucler E, Svedberg LE: **Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)**. *Heart* 2011, **97**(10):797-802.
178. Amneal: **Esomeprazole Strontium**. In: *US Product Monograph*. August 2013 edn. Glasgow, KY USA: Amneal Pharmaceuticals; 2013.
179. AstraZeneca Canada Inc: **Nexium (esomeprazole)**. In: *CA Product Monograph*. November 27, 2017 edn. Mississauga, Ontario: AstraZeneca Canada Inc.; 2017.
180. BC Provincial Academic Detailing Service: **Proton Pump Inhibitors**. In. Edited by Health Mo. Vancouver; 2015.
181. Takeda Pharmaceuticals America I: **Prevacid**. In: *Product Monograph*. Deerfield, Illinois: Takeda Pharmaceuticals America, Inc.; 2017.
182. Takeda: **Prevacid**. In: *US Product Monograph*. June 2018 edn. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2018.
183. Graham DY, Agrawal NM, Campbell DR, Haber MM, Collis C, Lukasik NL, Huang B: **Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole**. *Arch Intern Med* 2002, **162**(2):169-175.
184. Takeda: **Prevacid (lansoprazole)**. In: *CA Product Monograph*. September 4, 2018 edn. Deerfield, Illinois Takeda Pharmaceuticals America, Inc. ; 2018.

185. Inc. AC: **Losec**. In: *Product Monograph*. Mississauga, ON: AstraZeneca; 2016.
186. Covis: **Prilosec**. In: *US Product Monograph*. August 2018 edn. Zug, Switzerland: Covis Pharma; 2018.
187. Regula J, Butruk E, Dekkers CP, de Boer SY, Raps D, Simon L, Terjung A, Thomas KB, Luhmann R, Fischer R: **Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole**. *Am J Gastroenterol* 2006, **101**(8):1747-1755.
188. AstraZeneca Canada Inc: **Losec (omeprazole)**. In: *CA Product Monograph*. November 27, 2017 edn. Mississauga, Ontario: AstraZeneca Canada Inc.; 2017.
189. Inc. TC: **Pantoloc**. In: *Product Monograph*. Oaskville, ON: Takeda Canada Inc.; 2016.
190. Inc. TC: **Tecta**. In: *Product Monograph*. Takeda Canada Inc.; 2016.
191. Pfizer: **Protonix**. In: *US Product Monograph*. June 2018 edn. Philadelphia, PA USA: Pfizer; 2018.
192. Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F, Santagada T: **Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study**. *Dig Liver Dis* 2000, **32**(3):201-208.
193. Stupnicki T, Dietrich K, Gonzalez-Carro P, Straszak A, Terjung A, Thomas KB, Luhmann R, Fischer R: **Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients**. *Digestion* 2003, **68**(4):198-208.
194. Takeda: **Pantaloc (pantoprazole)**. In: *CA Product Monograph*. March 26, 2018 edn. Oakville, ON: Takeda Canada Inc. ; 2018.
195. Janssen: **Pariet**. In: *Product Monograph*. Toronto, ON: Janssen Inc.; 2016.
196. Eisai: **Aciphex**. In: *US Product Monograph*. June 2018 edn. Woodcliff Lake, NJ: Eisai Inc.; 2018.
197. Luo JC, Huang KW, Leu HB, Chen LC, Hou MC, Li CP, Lu CL, Lin HC, Lee FY, Lee SD: **Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer**. *Aliment Pharmacol Ther* 2011, **34**(5):519-525.
198. Janssen: **Pariet (rabeprazole)**. In: *CA Product Monograph*. November 21, 2018 edn. Toronto, Ontario Janssen Inc; 2018.

199. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD: **Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.** *PLoS One* 2013, **8**(4):e62162.
200. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G: **Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.** *Helicobacter* 2008, **13**(6):532-541.
201. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH: **The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.** *Am J Gastroenterol* 2006, **101**(7):1467-1475.
202. Williams MP, Pounder RE: **Review article: the pharmacology of rabeprazole.** *Aliment Pharmacol Ther* 1999, **13 Suppl 3**:3-10.
203. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T: **Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.** *J Gastroenterol Hepatol* 2002, **17**(7):748-753.
204. Inc. AP: **Misoprostol.** In: *Product Monograph.* Toronto, Ontario: AA Pharma Inc.; 2010.
205. Pfizer: **Cytotec.** In: *US Product Monograph.* January 2017 edn. New York, NY: Pfizer; 2017.
206. CPhA: **Misoprostol.** In: *Product Monograph.* CPhA; 2012.
207. AA: **Misoprostol** In: *CA Product Monograph.* May 28, 2010 edn. Toronto, Ontario: AA PHARMA INC.; 2010.
208. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S *et al*: **Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.** *Clin Pharmacol Ther* 2014, **95**(4):376-382.
209. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clin Pharmacol Ther* 2011, **89**(5):662-673.
210. **Dutch Guidelines.** [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
211. Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW *et al*: **Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite.** *Arch Pharm Res* 2017, **40**(3):382-390.

212. Liu R, Gong C, Tao L, Yang W, Zheng X, Ma P, Ding L: **Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects.** *Eur J Pharm Sci* 2015, **79**:13-19.
213. Murto K, Lamontagne C, McFaul C, MacCormick J, Ramakko KA, Aglipay M, Rosen D, Vaillancourt R: **Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study.** *Can J Anaesth* 2015, **62**(7):785-797.
214. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F *et al*: **Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.** *Gastroenterology* 2007, **133**(2):465-471.
215. Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA: **Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.** *Br J Pharmacol* 2004, **141**(2):205-208.
216. Prieto-Perez R, Ochoa D, Cabaleiro T, Roman M, Sanchez-Rojas SD, Talegon M, Abad-Santos F: **Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.** *J Clin Pharmacol* 2013, **53**(12):1261-1267.
217. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J: **Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.** *Pharmacogenetics* 2003, **13**(8):473-480.
218. Figueiras A, Estany-Gestal A, Aguirre C, Ruiz B, Vidal X, Carvajal A, Salado I, Salgado-Barreira A, Rodella L, Moretti U *et al*: **CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.** *Pharmacogenet Genomics* 2016, **26**(2):66-73.
219. Aithal GP, Day CP, Leathart JB, Daly AK: **Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.** *Pharmacogenetics* 2000, **10**(6):511-518.
220. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J: **Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.** *Br J Clin Pharmacol* 2003, **55**(1):51-61.
221. Agundez JA, Garcia-Martin E, Martinez C: **Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?** *Expert Opin Drug Metab Toxicol* 2009, **5**(6):607-620.
222. Wong CA, McCarthy RJ, Blouin J, Landau R: **Observational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesia.** *Int J Obstet Anesth* 2010, **19**(3):246-253.

223. De Gregori M, Diatchenko L, Ingelmo PM, Napolioni V, Klepstad P, Belfer I, Molinaro V, Garbin G, Ranzani GN, Alberio G *et al*: **Human Genetic Variability Contributes to Postoperative Morphine Consumption**. *J Pain* 2016, **17**(5):628-636.
224. Choi SW, Lam DMH, Wong SSC, Shiu HHC, Wang AXM, Cheung CW: **Effects of Single Nucleotide Polymorphisms on Surgical and Postsurgical Opioid Requirements: A Systematic Review and Meta-Analysis**. *Clin J Pain* 2017, **33**(12):1117-1130.
225. Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevs Smitt PA, van Schaik RH: **Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement**. *Pharmacogenomics* 2017, **18**(12):1133-1142.
226. Aubrun F, Zahr N, Langeron O, Boccheciampe N, Cozic N, Belin L, Hulot JS, Khiami F, Riou B: **Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study**. *Eur J Anaesthesiol* 2018, **35**(7):496-504.
227. Zhang J, Zhang L, Zhao X, Shen S, Luo X, Zhang Y: **Association between MDR1/CYP3A4/OPRM1 gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women**. *Gene* 2018, **661**:78-84.
228. Yoshida K, Nishizawa D, Ichinomiya T, Ichinohe T, Hayashida M, Fukuda K, Ikeda K: **Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses**. *PLoS One* 2015, **10**(1):e0116885.
229. Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A, Saita N, Koukita Y, Nagashima M, Katoh R *et al*: **Genome-wide association study identifies a potent locus associated with human opioid sensitivity**. *Mol Psychiatry* 2014, **19**(1):55-62.
230. Mouly S, Bloch V, Peoc'h K, Houze P, Labat L, Ksouda K, Simoneau G, Decleves X, Bergmann JF, Scherrmann JM *et al*: **Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity**. *Br J Clin Pharmacol* 2015, **79**(6):967-977.
231. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM: **Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome**. *Jama* 2013, **309**(17):1821-1827.
232. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, Huang CL, Lane HY: **Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients**. *Pharmacogenomics* 2011, **12**(11):1525-1533.
233. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Broesen K: **Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain**. *J Clin Pharmacol* 2012, **52**(2):234-242.

234. Lotsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, Rohrbacher M, Sittl R, Geisslinger G: **Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.** *Pharmacogenet Genomics* 2009, **19**(6):429-436.
235. Campa D, Gioia A, Tomei A, Poli P, Barale R: **Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief.** *Clin Pharmacol Ther* 2008, **83**(4):559-566.
236. Reyes-Gibby CC, Shete S, Ravvag T, Bhat SV, Skorpen F, Bruera E, Kaasa S, Klepstad P: **Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.** *Pain* 2007, **130**(1-2):25-30.
237. Arafa MH, Atteia HH: **Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.** *Toxicol Appl Pharmacol* 2018, **346**:37-44.
238. Dong H, Lu SJ, Zhang R, Liu DD, Zhang YZ, Song CY: **Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients.** *Eur J Clin Pharmacol* 2015, **71**(6):681-686.
239. Liu YC, Wang WS: **Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy.** *Cancer* 2012, **118**(6):1718-1725.
240. Cajanus K, Neuvonen M, Koskela O, Kaunisto MA, Neuvonen PJ, Niemi M, Kalso E: **Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?** *Clin Pharmacol Ther* 2018, **103**(4):653-662.
241. Balyan R, Mecoli M, Venkatasubramanian R, Chidambaran V, Kamos N, Clay S, Moore DL, Mavi J, Glover CD, Szmuk P *et al*: **CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.** *Pharmacogenomics* 2017, **18**(4):337-348.
242. Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G: **Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers.** *Ther Drug Monit* 2013, **35**(4):466-472.
243. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F: **CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.** *PLoS One* 2013, **8**(3):e60239.
244. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstrom S, Kaasa S, Dale O: **Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.** *Eur J Clin Pharmacol* 2012, **68**(1):55-64.
245. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: **Genetic polymorphisms and drug interactions**

- modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.** *Br J Pharmacol* 2010, **160**(4):919-930.
246. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH: **Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.** *Acta Anaesthesiol Scand* 2010, **54**(2):232-240.
247. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH: **The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.** *Basic Clin Pharmacol Toxicol* 2009, **104**(4):335-344.
248. de Leon J, Dinsmore L, Wedlund P: **Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.** *J Clin Psychopharmacol* 2003, **23**(4):420-421.
249. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D: **Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone.** *J Pain Symptom Manage* 1996, **12**(3):182-189.
250. Upjohn Canada: **Celebrex (celecoxib).** In: *CA Product Monograph.* Kirkland, QC; 2022.
251. Bryant Ranch Prepack: **Celebrex - celecoxib.** In: *US Product Monograph.* Burbank, CA; 2022.
252. Apotex Inc: **Diclofenac Sodium Enteric Coated Tablets, Diclofenac Sodium Slow Release Tablets.** In: *CA Product Monograph.* Toronto, ON; 2020.
253. Teva Canada Limited: **Teva-Diclofenac-K (diclofenac potassium).** In: *CA Product Monograph.* Toronto, ON; 2021.
254. Actavis Elizabeth LLC: **Diclofenac sodium.** In: *US Product Monograph.* Elizabeth, New Jersey; 2020.
255. Oceanside Pharmaceuticals: **Diclofenac Sodium Extended-release Tablets.** In: *US Product Monograph.* Bridgewater, NJ; 2021.
256. Amici Pharmaceuticals: **Diclofenac Potassium.** In: *US Product Monograph.* Melville, NY; 2021.
257. Novartis Pharmaceuticals Canada Inc: **Votaren Voltaren SR (diclofenac sodium).** In: *CA Product Monograph.* Dorval, Quebec; 2019.
258. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
259. Novartis Pharmaceuticals Canada Inc: **Voltaren Rapide (diclofenac potassium).** In: *CA Product Monograph.* Dorval, Quebec; 2019.

260. Pharmaceuticals N: **Voltaren Rapide**. In: *Product Monograph*. Dorval, QC; 2016.
261. Mipharm: **Cambia**. In: *US Monograph*. 2009.
262. McCormack J, Carleton B, Calissi P: **Dosage Adjustment in Renal Impairment**. In: *Therapeutics*. Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
263. GlaxoSmithKline: **Voltaren Gel (diclofenac diethylamine)**. In: *CA Product Monograph*. Mississauga, ON; 2021.
264. GlaxoSmithKline: **Voltaren Gel (diclofenac diethylamine)**. In: *CA Product Monograph*. Mississauga, ON; 2022.
265. Bryant Ranch Prepack: **Voltaren (diclofenac sodium gel)**. In: *US Product Monograph*. Warren, NJ; 2020.
266. Paladin Labs: **Pennsaid (diclofenac sodium solution)**. In: *CA Product Monograph*. St-Laurent, QC; 2022.
267. Horizon Therapeutics Inc: **Pennsaid (diclofenac sodium solution)**. In: *US Product Monograph*. Deerfield, IL; 2022.
268. Apotex Inc: **Apo-Ibuprofen**. In: *CA Product Monograph*. Toronto, Ontario; 2020.
269. Amneal Pharmaceuticals: **Ibuprofen**. In: *US Product Monograph*. January 2021 edn. Bridgewater, NJ: Amneal Pharmaceuticals; 2021.
270. Lexi-Drugs: **Ibuprofen**. In: *Lexicomp*. 2018.
271. Sanis Health Inc: **Meloxicam**. In: *CA Product Monograph*. Brampton, ON; 2022.
272. Inc. RPH: **Meloxicam**. In: *US Product Monograph*. East Brunswick, NJ; 2021.
273. Boehringer Ingelheim Pharmaceuticals: **Mobic (meloxicam)**. In: *US Product Monograph*. Ridgefield, CT; 2018.
274. Lupin Pharmaceuticals Inc: **Meloxicam**. In: *US Product Monograph*. Baltimore, MD; 2020.
275. Methapharm Inc: **Anaprox, Anaprox DS**. In: *CA Product Monograph*. Brantford, ON; 2022.
276. Methapharm Inc: **Naprosyn (naproxen)**. In: *CA Product Monograph*. Brantford, ON; 2022.
277. Amazon.com Services: **Naproxen Sodium**. In: *US Product Monograph*. Seattle, WA; 2022.
278. Canton Laboratories LLC: **Naprosyn (naproxen)**. In: *US Product Monograph*. Alpharetta, GA; 2019.

279. Almatica Pharma Inc: **Naprelan (naproxen sodium extended release)**. In: *US Product Monograph*. 2021.
280. Methapharm Inc: **Anaprox (naproxen sodium)**. In: *CA Product Monograph*. Brantford, ON; 2015.
281. Bayer Inc: **Aleve (naproxen sodium)**. In: *CA Product Monograph*. Mississauga, ON; 2019.
282. Almatica Pharma Inc: **Naprelan (naproxen sodium)**. In: *US Product Monograph*. Morristown, NJ; 2019.
283. Pharma A: **Anaprox**. In: *Product Monograph*. Basidon, Essex; 2015.
284. inc A: **Apo-Naproxen**. In: *Product Monograph*. 2015.
285. Lexi-Drugs: **Naproxen**. In: *Lexicomp*. 2018.
286. Atnahs: **Naprosyn (naproxen)**. In: *US Monograph*. Aug 2016 edn. Basildon, Essex, SS14 3FR, United Kingdom: Atnahs Pharma; 2016.
287. Bayer Inc. Consumer Care: **Aleve**. In: *Product Monograph*. Mississauga: Bayer Inc. Consumer Care; 2017.
288. Atnahs Pharma UK Limited: **Anaprox**. In: *Product Monograph*. Basildon, Essex: Atnahs Pharma UK Limited; 2015.
289. Law S, Derry S, Moore RA: **Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults**. *The Cochrane database of systematic reviews* 2016, **4**:Cd008541.
290. Association CP: **Nonsteroidal Anti-inflammatory Drugs (CPhA)**. In: *Product Monograph*. 2014.
291. Pfizer Canada Inc.: **DEPO-MEDROL**. In: *CA Product Monograph*. Kirkland, Quebec: Pfizer Canada Inc.; 2021.
292. Pharmacia & Upjohn Company: **Depo-Medrol**. In: *US Product Monograph*. 2021.
293. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2021.
294. Pfizer: **Depo-Medrol**. In: *US Product Monograph*. Dec 2020 edn. New York, NY USA: Pfizer 2020.
295. Bristol-Myers Squibb Canada: **Triamcinolone Acetonide Injectable Suspension USP**. In: *CA Product Monograph*. Montreal, QC; 2021.

296. E.R. Squibb & Sons: **Kenalog-40 Injection**. In: *US Product Monograph*. Princeton, NJ: Bristol-Myers Squibb; 2021.
297. Pharmaceuticals M: **Acetaminophen**. In: *FDA Monograph*. New Castle, DE; 2021.
298. **Adult Drug Book**. In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2021.
299. Johnson&Johnson: **Acetaminophen**. In: *FDA Monograph*. 2018.
300. Pharma A: **Acetaminophen Injection**. In: *CA Monograph*. 2018.
301. Fresenius: **Acetaminophen Injection**. In: *FDA Monograph*. 2015.
302. Angita Pharma Inc: **AG-Duloxetine**. In: *CA Product Monograph*. November 22, 2021 edn. Boucherville, QC; 2021.
303. Eli Lilly and Company: **Cymbalta (duloxetine)**. In: *US Product Monograph*. Indianapolis, IN; 2021.
304. ELI LILLY CANADA INC: **Cymbalta (duloxetine)**. In: *CA Product Monograph*. Toronto, ON; 2019.
305. Lilly USA: **Cymbalta (duloxetine)**. In: *US Product Monograph*. Indianapolis, IN; 2020.
306. Apotex Inc: **Apo-Tramadol**. In: *CA Product Monograph*. Toronto, Ontario; 2021.
307. Health B: **Ralivia (Tramadol Extended-Release)**. In: *CA Product Monograph*. Laval, QC; 2021.
308. Purdue Pharma: **Zytram XL (tramadol)**. In: *CA Product Monograph*. Pickering, ON; 2020.
309. Janssen Pharmaceuticals Inc: **Ultram (tramadol)**. In: *US Product Monograph*. Titusville, New Jersey; 2021.
310. Vertical Pharmaceuticals LLC: **Conzip (tramadol)**. In: *US Product Monograph*. Bridgewater, NJ; 2022.
311. Janssen Inc: **Ultram (tramadol)**. In: *CA Product Monograph*. Toronto, Ontario; 2020.
312. Cipher Pharmaceuticals Inc: **Durela (tramadol)**. In: *CA Product Monograph*. Mississauga, Ontario; 2018.
313. Purdue Pharma: **Zytram XL (tramadol)**. In: *CA Product Monograph*. Pickering, ON; 2018.



314. Janssen Pharmaceuticals Inc: **Ultram (tramadol)**. In: *US Product Monograph*. Titusville, New Jersey; 2019.
315. Vertical Pharmaceuticals LLC: **Conzip (tramadol)**. In: *US Product Monograph*. Bridgewater, NJ; 2019.